Yaokun Liu
Overview
Explore the profile of Yaokun Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
3
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang Y, Liu Y, Zhang B, Yang F, Gong Y, Zheng B, et al.
Perioper Med (Lond)
. 2024 Oct;
13(1):103.
PMID: 39402685
Simplified rapid hydration has been proven to be non-inferior to standard hydration in preventing contrast-associated acute kidney injury among chronic kidney disease patients undergoing coronary angiography. The current investigation aimed...
2.
Luo X, Liu Y, Liu J, Zhang J, Gao S, Zhang Y, et al.
Cardiology
. 2023 Sep;
149(1):78-92.
PMID: 37708863
Introduction: The main aim of this study was to investigate the impact of isolated coronary microvascular disease (CMD) as diagnosed via various modalities on prognosis. Methods: A systematic literature review...
3.
Liu Y, Zheng B, Zhang B, Ndondo-Lay R, Nie F, Tang N, et al.
Front Cardiovasc Med
. 2022 Aug;
9:938519.
PMID: 35935636
Objectives: Using quantitative coronary angiography (QCA), optical coherence tomography (OCT), histomorphometry, and pharmacokinetics, this study tried to evaluate the safety and efficacy of Biomagic rapamycin-eluting bioabsorbable scaffold (BVS) in non-atherosclerotic...
4.
Liu J, Fan F, Luo X, Ji W, Liu Y, Zhang Y, et al.
Front Cardiovasc Med
. 2021 Dec;
8:758956.
PMID: 34888364
A large amount of evidence suggests that proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors have clinical benefits in patients with cardiovascular disease (CVD). However, whether PCSK9 concentrations predict future cardiovascular...